Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Budget Crunch Forces CDRH To Abbreviate Baseline Device GMP Inspections

This article was originally published in The Gray Sheet

Executive Summary

CDRH plans to dramatically increase its inspections of domestic medical device facilities performed this year by reviewing only two of the four major QSIT subsystems in each "baseline" audit.

You may also be interested in...



QS Corrections & Removals Require Strong Customer Advocacy – Exec

Creation of a multi-discipline "customer advocacy team" to handle all non-sales calls can help device firms foresee and prepare for potential product or quality system problems, Alaris Medical Systems VP-Quality & Regulatory Affairs Bill Murphy suggested at RAPS' recent medical device conference

QS Corrections & Removals Require Strong Customer Advocacy – Exec

Creation of a multi-discipline "customer advocacy team" to handle all non-sales calls can help device firms foresee and prepare for potential product or quality system problems, Alaris Medical Systems VP-Quality & Regulatory Affairs Bill Murphy suggested at RAPS' recent medical device conference

CDRH Mulls Alternative Inspection Methods, Random-Sampling Audits

FDA expects to begin auditing randomly selected manufacturers of low risk devices by the first quarter of 2002, FDA staffers suggest following submission of the proposal to the Office of Regulatory Affairs.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel